STOCK TITAN
  1. Home
  2. Sec-filings
  3. NAMSW
  4. [Form 4] NewAmsterdam Pharma Co N.V. Insider Trading Activity

NewAmsterdam Pharma (NAMS) CAO exercises options and sells ordinary shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer, Louise Frederika Kooij, reported multiple option exercises and share sales in January 2026. On January 23, 2026, she exercised options for 38,172 ordinary shares at an exercise price of $10.90 per share, then sold 25,405 shares at a weighted average price of $33.44 and 12,767 shares at a weighted average price of $34.37, all as ordinary shares.

On January 26, 2026, she exercised additional options for 34,400 ordinary shares at $10.90 per share and sold 34,091 shares at a weighted average price of $32.77 and 309 shares at a weighted average price of $33.45. After these transactions, she directly owned 24,353 ordinary shares and held 145,562 options (right to buy) for ordinary shares.

Positive

  • None.

Negative

  • None.
Insider Kooij Louise Frederika
Role Chief Accounting Officer
Sold 72,572 shs ($2.42M)
Type Security Shares Price Value
Exercise Option (right to buy) 34,400 $0.00 --
Exercise Ordinary Shares 34,400 $10.90 $375K
Sale Ordinary Shares 34,091 $32.77 $1.12M
Sale Ordinary Shares 309 $33.45 $10K
Exercise Option (right to buy) 38,172 $0.00 --
Exercise Ordinary Shares 38,172 $10.90 $416K
Sale Ordinary Shares 25,405 $33.44 $850K
Sale Ordinary Shares 12,767 $34.37 $439K
Holdings After Transaction: Option (right to buy) — 145,562 shares (Direct); Ordinary Shares — 58,753 shares (Direct)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.06 to $34.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.06 to $34.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.40 to $33.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.40 to $33.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kooij Louise Frederika
(Last) (First) (Middle)
C/O NEWAMSTERDAM PHARMA COMPANY N.V.
GOOIMEER 2-35
(Street)
NAARDEN P7 1411 DC
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 01/23/2026 M 38,172 A $10.9 62,525 D
Ordinary Shares 01/23/2026 S 25,405 D $33.44(1) 37,120 D
Ordinary Shares 01/23/2026 S 12,767 D $34.37(2) 24,353 D
Ordinary Shares 01/26/2026 M 34,400 A $10.9 58,753 D
Ordinary Shares 01/26/2026 S 34,091 D $32.77(3) 24,662 D
Ordinary Shares 01/26/2026 S 309 D $33.45(4) 24,353 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) $10.9 01/23/2026 M 38,172 (5) 01/01/2033 Ordinary Shares 38,172 $0.00 179,962 D
Option (right to buy) $10.9 01/26/2026 M 34,400 (5) 01/01/2033 Ordinary Shares 34,400 $0.00 145,562 D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.06 to $34.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.06 to $34.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.40 to $33.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.40 to $33.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
5. The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
/s/ Louise Kooij 01/27/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did NAMS Chief Accounting Officer report?

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma (NAMS), reported exercising stock options and selling ordinary shares in January 2026. The filing details option exercises at $10.90 per share followed by multiple open‑market sales at higher weighted average prices.

How many NewAmsterdam Pharma (NAMS) shares did the CAO sell?

The CAO sold several blocks of NewAmsterdam Pharma ordinary shares: 25,405 shares at $33.44, 12,767 shares at $34.37, 34,091 shares at $32.77, and 309 shares at $33.45, all at weighted average prices disclosed in the filing footnotes.

At what price were NewAmsterdam Pharma (NAMS) options exercised?

The reported stock options were exercised at an exercise price of $10.90 per ordinary share. On January 23, 2026, 38,172 options were exercised, and on January 26, 2026, an additional 34,400 options were exercised at this same price.

How many NewAmsterdam Pharma (NAMS) shares does the CAO own after these trades?

After the January 2026 transactions, the CAO directly owns 24,353 ordinary shares of NewAmsterdam Pharma. The Form 4 also shows she holds 145,562 options (rights to buy ordinary shares) following the reported option exercises and share sales.

What weighted average prices were reported for NAMS share sales?

The filing reports weighted average sale prices for NewAmsterdam Pharma ordinary shares: $33.44 with trades from $33.06–$34.05, $34.37 with trades from $34.06–$34.75, $32.77 with trades from $32.40–$33.38, and $33.45 with trades from $33.40–$33.51.

What are the vesting terms of the NewAmsterdam Pharma (NAMS) options?

The option referenced was granted on January 1, 2023. According to the footnote, 25% vests on the one‑year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments over three years, subject to continued service.